
Loading, please wait...

Loading, please wait...

Modern cardiac electrophysiology continues to evolve rapidly as physiological pacing strategies challenge traditional device therapy paradigms. Specifically, left bundle branch pacing has emerged as a groundbreaking technique to preserve and restore physiological ventricular activation. Patients presenting with complete left bundle branch block frequently experience mechanical dyssynchrony, progressive ventricular dilatation, and deteriorating systolic function. Conventional guidelines typically mandate cardiac resynchronization therapy only when the left ventricular ejection fraction falls to thirty-five percent or lower. Consequently, patients exhibiting mildly to moderately reduced systolic function between thirty-six and fifty percent often receive guideline-directed medical therapy alone. However, observational registries indicate that persistent electrical dyssynchrony in this intermediate cohort accelerates clinical deterioration and increases adverse cardiovascular events. Pharmacological management alone frequently fails to correct underlying electromechanical delay. Therefore, clinicians increasingly explore whether physiological pacing can prevent irreversible myocardial injury when deployed before severe systolic impairment develops. Conduction system pacing directly captures specialized left-sided conduction tissue, rapidly depolarizing both ventricles along natural purkinje networks. By correcting dyssynchrony early, electrophysiologists aim to promote reverse remodeling before extensive myocardial fibrosis takes hold.
The landmark EARLY-RESYNC randomized trial provides essential prospective evidence addressing early pacing strategies. Investigators designed this multicenter study to evaluate the therapeutic impact of early physiological pacing against guideline-directed medical therapy alone. Specifically, researchers enrolled thirty-seven adult patients with complete left bundle branch block and mildly to moderately impaired ejection fractions ranging from thirty-six to fifty percent. The study population presented a mean age of 60.5 years, with females accounting for nearly sixty percent of enrolled participants. Furthermore, the baseline left ventricular ejection fraction averaged 42.6 percent, confirming significant systolic impairment. Investigators randomly allocated nineteen patients to receive early resynchronization using left bundle branch pacing combined with medical therapy. Meanwhile, eighteen control participants received medical therapy alone under standard clinical surveillance. The investigators defined the primary endpoint as the between-group difference in ejection fraction change from baseline to six months. In addition, secondary endpoints evaluated changes in left ventricular volumes and clinical outcomes. Importantly, researchers conducted all analyses according to the intention-to-treat principle, ensuring methodological rigor and minimizing potential selection bias.
At the six-month follow-up, the EARLY-RESYNC trial revealed substantial improvements favoring early intervention. Specifically, patients in the early pacing cohort achieved a markedly greater adjusted mean increase in ejection fraction compared to those receiving medical therapy alone. The adjusted between-group mean difference reached 7.4 percent, with a ninety-five percent confidence interval ranging from 1.9 to 12.9 percent. This primary finding demonstrated robust statistical significance with a p-value of 0.013. Moreover, sensitivity analyses using the per-protocol population confirmed these positive results with remarkable consistency. In addition to systolic improvement, early pacing produced significant structural reverse remodeling throughout the left ventricle. Paced patients experienced a pronounced mean reduction in left ventricular end-systolic volume of 23.6 milliliters compared to control subjects. Consequently, this structural shrinkage reflects genuine mechanical unloading rather than transient hemodynamic variability. Perhaps most remarkably, 78.9 percent of paced patients achieved a final ejection fraction of fifty percent or higher at six months. In contrast, only 38.9 percent of medically treated patients crossed this normal physiological threshold. Thus, early pacing doubled normalization rates.
Understanding why conduction system pacing outperforms traditional approaches requires examining ventricular electrophysiology. When complete bundle branch block develops, transseptal electrical propagation slows, generating profound dyssynchrony between the interventricular septum and the lateral wall. Conventional biventricular pacing attempts to resolve this problem by placing an epicardial lead through the coronary sinus. Although biventricular pacing improves outcomes in severe systolic failure, coronary venous anatomy often restricts optimal lead placement. Furthermore, epicardial wavefronts can create regional dispersion of repolarization and proarrhythmic substrates. In contrast, conduction system pacing places a pacing lead transseptally into the deep interventricular septum, directly capturing the native conduction system. Consequently, electrical impulses traverse the specialized His-Purkinje network rapidly, generating a remarkably narrow and physiological QRS complex. Because native endocardial activation patterns remain preserved, mechanical contraction occurs synchronously throughout both ventricles. This physiological synchrony reduces regional myocardial stretch, improves left ventricular pump efficiency, and decreases wall stress. As a result, the myocardium undergoes rapid reverse structural remodeling. Ultimately, direct conduction system recruitment restores coordinated contraction without inducing pacing-induced dyssynchrony.
The findings from EARLY-RESYNC challenge existing guidelines that restrict resynchronization solely to patients with severe systolic impairment. Currently, international professional guidelines assign class I recommendations for resynchronization almost exclusively to patients with ejection fractions below thirty-five percent. Consequently, individuals exhibiting intermediate impairment between thirty-six and fifty percent endure a therapeutic gap where disease progression continues unchecked. Although guideline-directed medical therapy remains foundational, pharmacotherapy alone cannot directly correct structural bundle branch delay. Therefore, delaying device intervention until the ejection fraction falls below thirty-five percent exposes patients to ongoing adverse remodeling. In contrast, early mechanical resynchronization fundamentally alters this disease trajectory by promoting early myocardial recovery. Furthermore, achieving normal systolic function in nearly eighty percent of patients may significantly reduce long-term arrhythmic risks and future hospitalizations. From an implementation standpoint, conduction pacing offers notable procedural advantages, including stable pacing thresholds and accessible delivery systems. However, implanters require structured training to ensure safe septal deployment and avoid lead-related complications. As larger randomized multicenter trials validate these findings, physiological pacing will likely redefine management protocols for intermediate ventricular dysfunction.
The EARLY-RESYNC trial demonstrated that left bundle branch pacing combined with medical therapy significantly improved left ventricular ejection fraction compared to drug therapy alone. Specifically, patients receiving early pacing experienced an adjusted mean improvement of 7.4% at six months. In addition, the pacing group showed substantial reverse ventricular remodeling with a marked reduction in end-systolic volume. Overall, nearly eighty percent of paced patients achieved a normal ejection fraction above fifty percent.
Early intervention is critical because complete left bundle branch block causes progressive mechanical dyssynchrony and adverse remodeling. Consequently, delaying resynchronization until the ejection fraction drops below thirty-five percent can lead to irreversible myocardial fibrosis. By intervening earlier during intermediate dysfunction, clinicians can restore physiological electrical activation promptly. Therefore, early resynchronization halts progressive ventricular dilatation, preserves systolic function, and prevents long-term heart failure hospitalizations in vulnerable cardiovascular patients.
Left bundle branch pacing directly engages the native His-Purkinje conduction system, whereas conventional biventricular pacing relies on epicardial stimulation through the coronary sinus. As a result, left bundle pacing produces rapid, physiological ventricular depolarization with a narrower QRS complex. Furthermore, this physiological technique avoids coronary sinus venous anatomy limitations and phrenic nerve stimulation. Consequently, operators can achieve superior ventricular synchrony, lower pacing thresholds, and better hemodynamic recovery across diverse patient populations.
Disclaimer: This content is for informational and educational purposes only... Refer to the latest local and national guidelines for clinical practice.
References
1. Zhu H et al. Early Left Bundle Branch Pacing for Complete Left Bundle Branch Block and Left Ventricular Ejection Fraction of 36%-50%: The EARLY-RESYNC Randomized Trial. Europace. 2026 Nov 16. doi: undefined. PMID: 43036879.
2. Chen X, Liu X, Li R, et al. Long-Term Outcomes of Left Bundle-Branch Pacing vs Biventricular Pacing in Heart Failure: The HeartSync-LBBP Randomized Clinical Trial. JAMA Cardiol. 2026;9(5):450-458.
3. Glikson M, Nielsen JC, Kronborg MB, et al. 2021 ESC Guidelines on cardiac pacing and cardiac resynchronization therapy. Eur Heart J. 2021;42(35):3427-3520.

Read summarized clinical updates, watch expert medical content, and earn CME certifications right from your smartphone.


The randomized EARLY-RESYNC trial reveals that early left bundle branch pacing combined with guideline-directed medical therapy significantly improves LVEF and reduces LV end-systolic volume compared to medical therapy alone in patients with complete LBBB and mildly reduced ejection fraction (36%-50%).
Today

Public health experts urge policymakers to review rigorous clinical evidence before scaling up double fortified salt. With only half of India's anaemia cases stemming from iron deficiency, specialists highlight structural trial limitations, dietary diversity needs, and pending data from the SAMPADA national survey.
Today

Recent data from PGIMER reveals that young adults diagnosed with type 2 diabetes face an aggressive disease trajectory. They encounter severe cardiovascular and microvascular damage within five years, occurring at higher rates than in type 1 diabetes despite lower mean blood glucose levels.
Today

A clinical overview of resveratrol supplementation in mitigating exercise-induced muscle damage. This narrative review explores physiological mechanisms, reductions in soreness markers like creatine kinase, dosage strategies, and bioavailability enhancements for sports medicine and nutrition practitioners.
Today

A novel smartphone-assisted biosensor utilizing molecularly imprinted polymers and catalytic nanozymes offers antibody-free, enzyme-free urinary microalbumin testing, enabling rapid, low-cost point-of-care screening for early chronic kidney disease.
Today